Bleeding Events After Triple Antithrombotic Therapy Initiation.
- Conditions
- Bleeding
- Registration Number
- NCT03203980
- Lead Sponsor
- Central Hospital, Nancy, France
- Brief Summary
The optimal antithrombotic therapy for patients requiring anticoagulation after coronary stenting is unknown. Double platelets suppressive agents combined with oral anticoagulation (triple antithrombotic therapy) remains the Gold standard.
Our study aims at studying bleeding events occurring until 6 months after the initiation of triple antithrombotic therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
- patients requiring triple antithrombotic therapy, including double antiplatelets agents and oral anticoagulation
Exclusion Criteria
- history of bleeding
- patients already under triple antithrombotic therapy
- patients under vitamin K antagonists
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Bleeding events within 6 months since the initiation of triple antithrombotic therapy Bleeding events with clinical significance
- Secondary Outcome Measures
Name Time Method